Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets.

Richard B Warren,Bruce Strober,Jonathan I Silverberg,Emma Guttman,Philippe Andres,Jakob Felding,Deniz Tutkunkardas,Kim Kjøller,Morten O A Sommer,Lars E French

Journal of the European Academy of Dermatology and Venereology : JEADV（2023）

引用 3|浏览25

暂无评分

摘要

Orismilast IR displayed higher efficacy compared to placebo in patients with moderate-to-severe psoriasis at week 16. Orismilast MR had similar PK properties and fewer GI disorders compared to the IR formulation in healthy participants. Future development of orismilast will be based on the MR formulation.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要